Listening Well And Early To The Signs Of Alzheimer’s Disease
The stereotypical view of an Alzheimer’s patient as an elderly person needs to change and interventions made earlier in the disease course, while we wait for novel drug therapies, said experts at a recent virtual meeting.
You may also be interested in...
Funded by the UK government, The Rosalind Franklin Institute works with industrial and academic partners from across the UK to foster interdisciplinary research with “real impact.” Leaders from the growing institute talk to In Vivo about validating its success and what it means to seek truly ground-breaking innovation in 2021.
In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2021. Data provided by Biomedtracker.
Sublicensing rights, revenue considerations, licensed know-how and diligence milestones: getting these elements right in deals with academic institutions sets the tone for biotechs as they grow and seek partnering opportunities with big pharma.